Emily Hill Biography and Net Worth

CFO of Replimune Group

Emily Hill was previously the CFO of PTC Therapeutics where she supported the company's growth from clinical to commercial stage. Ms. Hill joined PTC shortly after the IPO to lead investor relations. Prior to joining PTC Therapeutics, Emily was Director of Investor Relations of Warner Chilcott where she was responsible for leading the function. Additionally, Ms. Hill was Senior Manager of Investor Relations at Genzyme Corporation. Prior to Genzyme, Emily was a Biotech Equity Research Associate at Summer Street Partners. Ms. Hill has an MBA with a concentration in Finance from Fordham University, a Master of Science in Pharmacology from Tufts University School of Biomedical Research, and a BA from Hamilton College.

What is Emily Luisa Hill's net worth?: The estimated net worth of Emily Luisa Hill is at least $748,832.37 as of August 16th, 2024. Ms. Hill owns 101,057 shares of Replimune Group stock worth more than $748,832 as of May 14th. This net worth approximation does not reflect any other assets that Ms. Hill may own. Learn More about Emily Luisa Hill's net worth.
How old is Emily Luisa Hill?: Ms. Hill is currently 44 years old. There are 9 older executives and no younger executives at Replimune Group. The oldest executive at Replimune Group is Dr. Colin A. Love Ph.D., Chief Operating Officer, who is 66 years old. Learn More on Emily Luisa Hill's age.
How do I contact Emily Luisa Hill?: The corporate mailing address for Ms. Hill and other Replimune Group executives is 500 Unicorn Park, WOBURN MA, 01801. Replimune Group can also be reached via phone at (781) 222-9600 and via email at ir@replimune.com. Learn More on Emily Luisa Hill's contact information.
Has Emily Luisa Hill been buying or selling shares of Replimune Group?: Emily Luisa Hill has not been actively trading shares of Replimune Group within the last three months. Most recently, Emily Luisa Hill sold 8,938 shares of the business's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a transaction totalling $90,988.84. Following the completion of the sale, the chief financial officer now directly owns 101,057 shares of the company's stock, valued at $1,028,760.26. Learn More on Emily Luisa Hill's trading history.
Who are Replimune Group's active insiders?: Replimune Group's insider roster includes Philip Astley-Sparke (Chairman), Robert Coffin (Insider), Pamela Esposito (Insider), Emily Hill (CFO), Colin Love (COO), Sushil Patel (CEO), Christopher Sarchi (Insider), Andrew Schwendenman (CAO), and Konstantinos Xynos (Chief Medical Officer). Learn More on Replimune Group's active insiders.
Are insiders buying or selling shares of Replimune Group?: During the last year, insiders at the sold shares 10 times. They sold a total of 133,782 shares worth more than $1,005,817.21. The most recent insider tranaction occured on December, 16th when CEO Sushil Patel sold 10,000 shares worth more than $124,200.00. Insiders at Replimune Group own 8.8% of the company. Learn More about insider trades at Replimune Group.
Information on this page was last updated on 12/16/2024.

Emily Luisa Hill Insider Trading History at Replimune Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/16/2024	Sell	8,938	$10.18	$90,988.84	101,057

Emily Luisa Hill Buying and Selling Activity at Replimune Group

Replimune Group Company Overview

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Today's Range

Now: $7.41

$7.40

$7.95

50 Day Range

MA: $9.27

$6.92

$12.11

2 Week Range

Now: $7.41

$4.92

$17.00

Volume

663,362 shs

Average Volume

896,252 shs

Market Capitalization

$570.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.68

Emily Hill Biography and Net Worth

What is Emily Luisa Hill's net worth?

How old is Emily Luisa Hill?

How do I contact Emily Luisa Hill?

Has Emily Luisa Hill been buying or selling shares of Replimune Group?

Who are Replimune Group's active insiders?

Are insiders buying or selling shares of Replimune Group?